Rare Variation and Remote Gene Regulation of Osteoporosis Related Phenotypes in Han Chinesse

Sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University (Other)
Overall Status
Unknown status
CT.gov ID
NCT04129671
Collaborator
Westlake University (Other)
3,000
1
32.1
93.5

Study Details

Study Description

Brief Summary

Bone density is recognized as the most important factor to measure osteoporosis, and the prevalence of osteoporosis increases with age. Risk factors for osteoporosis include age, weight, exercise, diet, smoking and alcohol consumption. What's more, osteoporosis has a strong familial aggregation, and the genetic value of bone density is between 0.6 and 0.85. Therefore, it is necessary to conduct large-scale collection of population samples of osteoporosis fractures and relevant genetic studies.

Condition or Disease Intervention/Treatment Phase
  • Genetic: No intervention was applied

Detailed Description

From past linkage analysis and candidate gene association studies to genome-wide association studies and second-generation sequencing technologies, researchers have found hundreds of genes and SNPs associated with bone mineral density and osteoporosis fractures. However, current studies on osteoporosis and related phenotypes are mainly concentrated in the European and American populations, rare in Asia and other regions, and even less in the Chinese han population. It is one of the problems to be solved in this project whether the genes and SNP loci associated with these strengths can also be applied to han Chinese population due to the existence of racial differences. This project aims to collect the patients with primary osteoporosis and osteoporosis fracture in the Chinese han population through the orthopaedics department, and verify the identified osteoporosis susceptibility genes in the Chinese han population.

Study Design

Study Type:
Observational
Anticipated Enrollment :
3000 participants
Observational Model:
Ecologic or Community
Time Perspective:
Prospective
Official Title:
Rare Variation and Remote Gene Regulation of Osteoporosis Related Phenotypes in Han Chinesse
Actual Study Start Date :
Apr 29, 2019
Anticipated Primary Completion Date :
Dec 1, 2021
Anticipated Study Completion Date :
Dec 31, 2021

Outcome Measures

Primary Outcome Measures

  1. Exon sequencing results from the target region [June 2018-December 2021]

    Exon sequencing

Eligibility Criteria

Criteria

Ages Eligible for Study:
50 Years to 100 Years
Sexes Eligible for Study:
All
Inclusion Criteria:
  1. From July 2018 to July 2021, patients admitted to the outpatient or inpatient clinic were diagnosed as primary osteoporosis fracture;

  2. Aged between 50 and 100;

  3. This fracture was not treated with any anti-osteoporosis drugs before

  4. Subjects will participate in the study voluntarily and have signed the informed consent

  5. Patients with clear mind and independent behavioral ability

Exclusion Criteria:
  1. Patients with malignant tumors are associated with bone metastases, such as lung cancer, prostate cancer, thyroid cancer, etc

  2. Hyperparathyroidism, Cushing syndrome, hypogonadism, hyperthyroidism, pituitary prolactinoma, diabetes

  3. Systemic lupus erythematosus, rheumatoid arthritis, sjogren's syndrome, dermatomyositis, mixed connective tissue disease, etc.;

  4. Renal osteodystrophy caused by various chronic kidney diseases;

  5. Gastrointestinal diseases and nutritional diseases: malabsorption syndrome, subtotal gastrectomy, chronic pancreatic diseases, chronic liver diseases, protein-calorie malnutrition, long-term intravenous nutrition support treatment, etc.;

  6. Leukemia, lymphoma, multiple myeloma, hyperthermia and myelodysplastic syndrome;

  7. Hemiplegia, paraplegia, motor dysfunction, muscular dystrophy, catalepsy and myotonic syndrome caused by various reasons;

  8. Glucocorticoids, immunosuppressants, heparin, anticonvulsants, anticancer drugs, aluminum-containing antacids, thyroid hormones, gnrh-a or dialysate, etc.

  9. Unwilling to accept dietary management or unable to sign the informed consent

Contacts and Locations

Locations

Site City State Country Postal Code
1 2nd Affiliated Hospital, School of Medicine, Zhejiang University, China Hangzhou Zhejing Province China 310009

Sponsors and Collaborators

  • Second Affiliated Hospital, School of Medicine, Zhejiang University
  • Westlake University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Shigui Yan, Honorary director of the department of orthopaedics surgery, Second Affiliated Hospital, School of Medicine, Zhejiang University
ClinicalTrials.gov Identifier:
NCT04129671
Other Study ID Numbers:
  • 2018-090
First Posted:
Oct 17, 2019
Last Update Posted:
Oct 17, 2019
Last Verified:
Oct 1, 2019
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 17, 2019